Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (261-270 of 999) with videos related to

Pageof 100
Sort By:
Circulation|February 6, 2004
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) studyChristie M Ballantyne, Ron C Hoogeveen, Heejung Bang, et al.
American Journal of Hypertension|September 20, 2008
Association of lactate with blood pressure before and after rapid weight lossStephen O Crawford, Marietta S Ambrose, Ron C Hoogeveen, et al.
Thrombosis and Haemostasis|October 9, 2018
Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities StudyNicholas S Roetker, Richard F MacLehose, Ron C Hoogeveen, et al.
Controlled Clinical Trials|December 1, 1996
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemiaM S West, J A Herd, C M Ballantyne, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Plos One|February 6, 2016
Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) StudyKhanh N Vu, Christie M Ballantyne, Ron C Hoogeveen, et al.
JAMA|July 7, 1989
Effects of cyclosporine therapy on plasma lipoprotein levelsC M Ballantyne, E J Podet, W P Patsch, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities studyAriel Brautbar, Christie M Ballantyne, Kim Lawson, et al.
Journal of Clinical Lipidology|February 5, 2011
Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analysesNicola Abate, Alberico L Catapano, Christie M Ballantyne, et al.
Clinical Chemistry|March 28, 2025
A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk?Yashika Parashar, Aya Awwad, Soahum Bagchi, et al.
Pageof 100

Showing results (261-270 of 999) with videos related to

Sort By:
Pageof 100
Circulation|February 6, 2004
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) studyChristie M Ballantyne, Ron C Hoogeveen, Heejung Bang, et al.
American Journal of Hypertension|September 20, 2008
Association of lactate with blood pressure before and after rapid weight lossStephen O Crawford, Marietta S Ambrose, Ron C Hoogeveen, et al.
Thrombosis and Haemostasis|October 9, 2018
Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities StudyNicholas S Roetker, Richard F MacLehose, Ron C Hoogeveen, et al.
Controlled Clinical Trials|December 1, 1996
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemiaM S West, J A Herd, C M Ballantyne, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Plos One|February 6, 2016
Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) StudyKhanh N Vu, Christie M Ballantyne, Ron C Hoogeveen, et al.
JAMA|July 7, 1989
Effects of cyclosporine therapy on plasma lipoprotein levelsC M Ballantyne, E J Podet, W P Patsch, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities studyAriel Brautbar, Christie M Ballantyne, Kim Lawson, et al.
Journal of Clinical Lipidology|February 5, 2011
Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analysesNicola Abate, Alberico L Catapano, Christie M Ballantyne, et al.
Clinical Chemistry|March 28, 2025
A Meta-Analysis and Systematic Review of Cardiac Troponin I vs T in Community Dwelling Adults: Is Specificity at Risk?Yashika Parashar, Aya Awwad, Soahum Bagchi, et al.
Pageof 100